Equity Profile

LGND

Ligand Pharmaceuticals Incorporated

Health CarePharmaceuticals$5.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ligand Pharmaceuticals Incorporated (LGND) is a healthcare company focused on developing and commercializing technologies that enhance the drug discovery process. With a market cap of $6 billion, Ligand plays a significant role in the pharmaceutical industry, especially as demand for innovative therapies continues to grow.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LGND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+287.89%

Avg Stock Reaction

+1.84%

Last Quarter Recap

In Q1 2026, Ligand reported an EPS of $1.63, significantly surpassing estimates by 66.84%. However, the stock fell by 9.55% the following day, indicating mixed investor sentiment despite the strong earnings surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Ligand's upcoming earnings report, especially given its history of beating EPS estimates.

Bull Case

If Ligand continues its trend of strong earnings surprises, it could lead to a significant uptick in stock price, especially if revenue growth is also robust.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, as seen in previous quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Ligand's history of EPS surprises, the market will closely watch this figure to gauge the company's financial health.

What guidance will management provide for future revenue growth?

Future revenue guidance will be critical for investor confidence, especially in light of recent stock price volatility.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Ligand's ability to sustain its earnings momentum, given its recent strong performance.

Supporting Evidence

Ligand has consistently beaten EPS estimates in the last eight quarters, indicating a strong operational track record.

The options market is pricing in a larger move than historical averages, suggesting that investors expect significant volatility.

The recent drop in stock price following strong earnings may indicate an overreaction rather than a fundamental weakness.

Key Risk

If the EPS comes in below $1.50, it could undermine the bullish sentiment and lead to a reassessment of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it will either reinforce Ligand's growth narrative or raise concerns about its future prospects.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.50 would confirm the bear case, suggesting potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±15.86%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±15.9% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

47.7%

Calls (100)P/C Ratio: 0.15Puts (300)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ligand beats expectations, history suggests a potential stock increase of around 1.84%, confirming the company's strong trajectory.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 9.55% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug development timelines and their potential impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Details on cost management and operational efficiencies.
4Insights into partnerships or collaborations that could drive future growth.
5Any changes in guidance for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LGND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+287.89%

Avg Stock Reaction

+1.84%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Ligand's upcoming earnings report, especially given its history of beating EPS estimates.

Bull Case

If Ligand continues its trend of strong earnings surprises, it could lead to a significant uptick in stock price, especially if revenue growth is also robust.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, as seen in previous quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Ligand's history of EPS surprises, the market will closely watch this figure to gauge the company's financial health.

What guidance will management provide for future revenue growth?

Future revenue guidance will be critical for investor confidence, especially in light of recent stock price volatility.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Ligand's ability to sustain its earnings momentum, given its recent strong performance.

Supporting Evidence

Ligand has consistently beaten EPS estimates in the last eight quarters, indicating a strong operational track record.

The options market is pricing in a larger move than historical averages, suggesting that investors expect significant volatility.

The recent drop in stock price following strong earnings may indicate an overreaction rather than a fundamental weakness.

Key Risk

If the EPS comes in below $1.50, it could undermine the bullish sentiment and lead to a reassessment of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it will either reinforce Ligand's growth narrative or raise concerns about its future prospects.

Bull Confirmed If

An EPS of $2.00 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.50 would confirm the bear case, suggesting potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±15.86%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±15.9% while LGND has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

47.7%

Calls (100)P/C Ratio: 0.15Puts (300)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ligand beats expectations, history suggests a potential stock increase of around 1.84%, confirming the company's strong trajectory.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 9.55% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug development timelines and their potential impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Details on cost management and operational efficiencies.
4Insights into partnerships or collaborations that could drive future growth.
5Any changes in guidance for the upcoming quarters.